Literature DB >> 11461795

Proof of efficacy trials: endpoints.

J A French1.   

Abstract

Seizure frequency data are difficult to work with because they are so variable both between and within patients. Seizures can come in clusters, thereby adding to the variation in seizure frequency. Also, seizure frequency data are non-parametric in nature, making them difficult to analyze by some statistical techniques without transforming them. Therefore, to improve data analysis in proof of efficacy studies, manipulations of seizure frequency are commonly used, such as the proportion of responders above an arbitrary threshold, or the response ratio. Other useful endpoints are time to nth seizure, number of seizure-free days, proportion of seizure-free patients, and assessment of seizure severity using rating scales. The choice of endpoint(s) will depend upon the design of the study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461795     DOI: 10.1016/s0920-1211(01)00216-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

1.  Comparing stimulant effects in youth with ADHD symptoms and epilepsy.

Authors:  Joseph Gonzalez-Heydrich; Olivia Hsin; Sarah Gumlak; Kara Kimball; Ashley Rober; Muhammad W Azeem; Meredith Hickory; Christine Mrakotsky; Alcy Torres; Enrico Mezzacappa; Blaise Bourgeois; Joseph Biederman
Journal:  Epilepsy Behav       Date:  2014-06-02       Impact factor: 2.937

2.  Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms.

Authors:  James D Frost; John T Le; Chong L Lee; Carlos Ballester-Rosado; Richard A Hrachovy; John W Swann
Journal:  Neurobiol Dis       Date:  2015-05-27       Impact factor: 5.996

3.  Understanding the Patient Perspective of Seizure Severity in Epilepsy: Development of a Conceptual Model.

Authors:  Simon Borghs; Erin L Tomaszewski; Katarina Halling; Christine de la Loge
Journal:  Patient       Date:  2016-10       Impact factor: 3.883

4.  Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy.

Authors:  Aristea S Galanopoulou; Wenzhu B Mowrey
Journal:  Epilepsia Open       Date:  2016-10-27

5.  Imepitoin is well tolerated in healthy and epileptic cats.

Authors:  Odilo Engel; Thilo von Klopmann; Arianna Maiolini; Jessica Freundt-Revilla; Andrea Tipold
Journal:  BMC Vet Res       Date:  2017-06-12       Impact factor: 2.741

6.  Pregabalin Add-On vs. Dose Increase in Levetiracetam Add-On Treatment: A Real-Life Trial in Dogs With Drug-Resistant Epilepsy.

Authors:  Sandra R P Kriechbaumer; Konrad Jurina; Franziska Wielaender; Henning C Schenk; Tanja A Steinberg; Sven Reese; Gesine Buhmann; Stefanie Doerfelt; Heidrun Potschka; Andrea Fischer
Journal:  Front Vet Sci       Date:  2022-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.